SC
VERV

Syon Capital’s Verve Therapeutics VERV Stock Holding History

Syon Capital’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,830
Closed -$178K – 848
2025
Q2 		$178K Sell
15,830
-41,461
-72% -$236K 0.01% 702
2025
Q1 		$262K Buy
57,291
+3,822
+7% +$25.6K 0.02% 464
2024
Q4 		$302K Buy
+53,469
New +$302K 0.03% 398

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Syon Capital's VERV Position: Q3 2025 in Review

Syon Capital sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 15,830 shares — an estimated $178K sold.

Syon Capital first reported a position in VERV in Q4 2024 and held it in 3 quarters. The position peaked at $302K in Q4 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Syon Capital reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Syon Capital sold 15,830 Verve Therapeutics shares in Q3 2025, an estimated $178K.
  • Syon Capital first reported a position in Verve Therapeutics in Q4 2024 and held it in 3 quarters.
  • Syon Capital's Verve Therapeutics position peaked at $302K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Syon Capital's 13F filing for Q3 2025, filed 7 Nov 2025.